It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims/hypothesis
Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.
Methods
In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years.
Results
DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes.
Conclusions/interpretation
HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024); Royal Devon and Exeter NHS Foundation Trust, Department of Diabetes and Endocrinology, Exeter, UK (GRID:grid.419309.6) (ISNI:0000 0004 0495 6261)
2 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024)
3 Imperial College, Faculty of Medicine, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
4 Pacific Northwest Research Institute, Seattle, USA (GRID:grid.280838.9) (ISNI:0000 0000 9212 4713)
5 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024); Royal Devon and Exeter NHS Foundation Trust, Renal Department, Exeter, UK (GRID:grid.419309.6) (ISNI:0000 0004 0495 6261)